Tadeusz Robak
YOU?
Author Swipe
View article: Successful outcome of multidrug-resistant autoimmune hemolytic anemia with daratumumab, bortezomib and cyclosporine therapy
Successful outcome of multidrug-resistant autoimmune hemolytic anemia with daratumumab, bortezomib and cyclosporine therapy Open
View article: Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy
Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy Open
In the ELM-2 study (NCT03888105) of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) (n = 141), odronextamab 160 mg weekly (after step-up dosing) significantly improved Functional Assessment of Cancer Ther…
View article: Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL Open
With up to 10 years of follow-up, we report results from the final analysis of RESONATE- 2, a phase 3 study of first-line ibrutinib vs chlorambucil for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Pat…
View article: Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2025
Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2025 Open
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, with a median age at diagnosis of about 70 years. The natural course of the disease varies greatly, and patients with non-progressive and asymptomatic leukemia do not require …
View article: 214 | FINAL INDEPENDENT REVIEW DATA SUPPORTS SUSTAINED BENEFIT OF ZANUBRUTINIB OVER IBRUTINIB IN PATIENTS WITH R/R CLL/SLL IN ALPINE
214 | FINAL INDEPENDENT REVIEW DATA SUPPORTS SUSTAINED BENEFIT OF ZANUBRUTINIB OVER IBRUTINIB IN PATIENTS WITH R/R CLL/SLL IN ALPINE Open
View article: 213 | COMBINATION OF ZANUBRUTINIB + VENETOCLAX FOR TREATMENT‐NAIVE CLL/SLL: RESULTS IN SEQUOIA ARM D
213 | COMBINATION OF ZANUBRUTINIB + VENETOCLAX FOR TREATMENT‐NAIVE CLL/SLL: RESULTS IN SEQUOIA ARM D Open
View article: Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ <i>TP53</i> Mutation: SEQUOIA Arm D Results
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ <i>TP53</i> Mutation: SEQUOIA Arm D Results Open
PURPOSE Several chronic lymphocytic leukemia (CLL) studies have demonstrated promising efficacy with the combination of BCL2 and Bruton tyrosine kinase inhibitors; however, patients with CLL with del(17p) and/or TP53 mutation ( TP53 mut) c…
View article: Venetoclax used alone, or in combination with cladribine, changes the expression of apoptosis-regulating genes in chronic lymphocytic leukemia cells in vitro
Venetoclax used alone, or in combination with cladribine, changes the expression of apoptosis-regulating genes in chronic lymphocytic leukemia cells in vitro Open
Venetoclax and 2-CdA may exert their pro-apoptotic effects on CLL cells in vitro, at least in part, by stimulating the expression of several apoptosis-related genes. The antileukemic activity of VEN is further enhanced when combined with 2…
View article: Acalabrutinib in treatment of patients with chronic lymphocytic leukemia including those at high genetic risk
Acalabrutinib in treatment of patients with chronic lymphocytic leukemia including those at high genetic risk Open
Acalabrutinib belongs to a class of Bruton’s tyrosine kinase inhibitors (BTKis) which have become one of the most widely used drugs for the treatment of B-cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma …
View article: Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia
Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia Open
The combination of ibrutinib and venetoclax represents the first fixed-duration oral treatment involving a Bruton tyrosine kinase inhibitor and a BCL2 inhibitor for adult patients with untreated chronic lymphocytic leukaemia. The phase 2 C…
View article: Double Strike in Chronic Lymphocytic Leukemia—The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice
Double Strike in Chronic Lymphocytic Leukemia—The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice Open
In the recent 2024 ESMO guidelines, the combination of venetoclax and ibrutinib was listed as one of the first-line treatment options for CLL patients. These drugs were first-in-class medicines that revolutionized CLL management, extending…
View article: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial Open
The phase 2, multicohort, ongoing ELM-2 study evaluates odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory (R/R) B cell non-Hodgkin lymphoma after ≥2 lines of therapy. Here primary analysis of the diffuse la…
View article: The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL Open
Fixed-duration venetoclax-rituximab (VenR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) in the phase 3 MURANO trial resulted in superior progression-free survival (PFS) and overall survival (OS) vs bendamustine-r…
View article: Accelerated chronic lymphocytic leukemia – characteristics and retrospective analysis of the Polish Adult Leukemia Study Group
Accelerated chronic lymphocytic leukemia – characteristics and retrospective analysis of the Polish Adult Leukemia Study Group Open
This study represents one of the largest datasets of A-CLL patients and shows its poorer prognosis compared to typical CLL. Chronic lymphocytic leukemia directed therapy should be considered as a treatment modality of choice for A-CLL. R-C…
View article: A rare case of Rosai-Dorfman disease mimicking a malignant lymphoproliferative process and IgG4-related disease
A rare case of Rosai-Dorfman disease mimicking a malignant lymphoproliferative process and IgG4-related disease Open
Rosai-Dorfman disease (RDD), or sinus histiocytosis with massive lymphadenopathy, is a rare histiocytic disorder that often mimics malignancies and immune-mediated conditions such as IgG4-related disease (IgG4-RD). We report a 73-year-old …
View article: Correction for: Accelerated chronic lymphocytic leukemia – characteristics and retrospectiveanalysis of the Polish Adult Leukemia Study Group
Correction for: Accelerated chronic lymphocytic leukemia – characteristics and retrospectiveanalysis of the Polish Adult Leukemia Study Group Open
[This corrects the article DOI: 10.5114/mp.2025.148753.].
View article: Benefits of infusion pump technology in treatment of patients with acquired hemophilia A and hemophilia A with inhibitor a Polish pilot observational study
Benefits of infusion pump technology in treatment of patients with acquired hemophilia A and hemophilia A with inhibitor a Polish pilot observational study Open
View article: Recombinant ADAMT S-13 as a new alternative for the patients with congenital thrombocytopenic purpura
Recombinant ADAMT S-13 as a new alternative for the patients with congenital thrombocytopenic purpura Open
Congenital thrombocytopenic purpura (cTTP), also known as Upshaw–Schulman syndrome is a rare disease, caused by ADAMTS13 deficiency. This condition may result in various complications, including haemolytic anaemia, renal dysfunction or thr…
View article: Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Predictors and Profile of Severe Infectious Complications in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens: A Machine Learning Model for Pneumonia Risk
Predictors and Profile of Severe Infectious Complications in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens: A Machine Learning Model for Pneumonia Risk Open
Background: Daratumumab (Dara) is the first monoclonal antibody introduced into clinical practice to treat multiple myeloma (MM). It currently forms the backbone of therapy regimens in both newly diagnosed (ND) and relapsed/refractory (RR)…
View article: The discovery of the <scp>RCC1</scp> :: <scp>IRF4</scp> Fusion in <scp>CLL</scp> patients with t(1;6)(p35.3;p25.2) chromosomal translocation
The discovery of the <span>RCC1</span> :: <span>IRF4</span> Fusion in <span>CLL</span> patients with t(1;6)(p35.3;p25.2) chromosomal translocation Open
Jayne et al. provide a molecular characterization of the t(1;6)(p35.3;p25.2) chromosomal translocation in patients with chronic lymphocytic leukaemia. They indicate that this translocation involves the gene encoding interferon regulatory f…
View article: Wrodzona hemofilia A powikłana inhibitorem leczona rekombinowanym czynnikiem VIIa podawanym w pompie infuzyjnej
Wrodzona hemofilia A powikłana inhibitorem leczona rekombinowanym czynnikiem VIIa podawanym w pompie infuzyjnej Open
View article: Congenital haemophilia A with inhibitor treated with recombinant factor VIIa in an infusion pump
Congenital haemophilia A with inhibitor treated with recombinant factor VIIa in an infusion pump Open
View article: Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE Open
The ALPINE trial established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; here, we present data from the final comparative analysis with ex…
View article: Increased abundance of <i>Firmicutes</i> and depletion of <i>Bacteroidota</i> predicts poor outcome in chronic lymphocytic leukemia
Increased abundance of <i>Firmicutes</i> and depletion of <i>Bacteroidota</i> predicts poor outcome in chronic lymphocytic leukemia Open
Evidence indicates that there are significant alterations in gut microbiota diversity and composition in patients with hematological malignancies. The present study investigated the oral and intestinal microbiome in patients with chronic l…
View article: Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial Open
This multicenter, open-label, phase 1b study (ACE-LY-106) assessed the safety and efficacy of acalabrutinib, bendamustine, and rituximab (ABR) in treatment-naive (TN) and relapsed or refractory (R/R) mantle cell lymphoma (MCL). Patients re…
View article: Rare Clinical Symptoms in Hairy Cell Leukemia: An Overview
Rare Clinical Symptoms in Hairy Cell Leukemia: An Overview Open
Background: Hairy cell leukemia (HCL) is a rare indolent B-cell lymphoid malignancy. The majority of patients are asymptomatic and HCL is usually diagnosed incidentally during a routine blood cell count. In symptomatic patients, typical sy…
View article: Effective treatment of autoimmune thrombocytopenia with rituximab in CLL patient undergoing therapy with acalabrutinib
Effective treatment of autoimmune thrombocytopenia with rituximab in CLL patient undergoing therapy with acalabrutinib Open
View article: CLL-076 Final Analysis of the RESONATE-2 Study: up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CLL-076 Final Analysis of the RESONATE-2 Study: up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Open
View article: Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Open